Allergan's Off-Label Suit Against FDA Will Continue Despite Botox Approval For Spasticity
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan is continuing to press for a court order that FDA's restrictions on off-label promotion are unconstitutional; a court hearing in the case is set for April 26.